Protocols

AstraZeneca auctions off more assets in $766M deal, reports positive data for Farxiga

AstraZeneca CEO Pascal Soriot has sold off another set of assets. The pharma giant is selling a portfolio of anesthetics to Aspen Global for $555 million in cash and $211 million in milestones. AstraZeneca has been steadily auctioning off a variety of assets as it focuses more and more on its new cancer franchise.

AstraZeneca has rolled out new data from a late-stage study that highlights how Farxiga, approved for Type 2 diabetes, also helps Type 1 patients. That’s a much smaller market, but an opening here could expand franchise sales. The drug is an SGLT-2 inhibitor with several rivals on the market.

Recipharm and the CRO Clinical Trial Consultants have partnered on a new service designed to provide a streamlined approach to gaining proof-of-concept data.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->